BIRC5 and malignant glioma: In this context, we tested the efficacy of this chemotherapy–virotherapy combination with TMZ and CRAd-Survivin-pk7 (CRAd-S-pk7), a novel oncolytic adenoviral vector that utilises the survivin promoter to drive E1A expression and binds to heparan sulphate proteoglycans expressed on malignant glioma (Ulasov et al, 2007; Zheng et al, 2007; Nandi et al, 2008).